Leiomyosarcoma
11 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Dacarbazine for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Definitive radiotherapy for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Echocardiography + Biospecimen Collection + Computed Tomography + Multigated Acquisition Scan + Zanzalintinib for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivonescimab for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lurbinectedin for leiomyosarcoma | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Proton beam radiation therapy + Surgical resection + SELINEXOR + PAZOPANIB + Doxorubicin + Ifosfamide for leiomyosarcoma | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Quality of Life + Functional outcome + preoperative for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Radiotherapy + TRABECTEDIN for leiomyosarcoma | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.